Novartis
-
Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients
Sep 20, 2016News Hour: Novartis announced positive results of the Phase III EXPAND study showing that oral once-daily BAF312 (siponimod) significantly reduced the risk of disability progression compared with placebo in people with secondary progressive multiple sclerosis (SPMS).SPMS... -
Benefit of Gilenya® on patient disability progression at 10 years
Sep 19, 2016News Hour: Novartis announced new data from the ACROSS study, which assessed 10-year disability outcomes in people with relapsing remitting multiple sclerosis (RRMS) treated with Gilenya® (fingolimod). These results provide supportive evidence of the long-term effectiveness... -
New positive data at EHMTIC showing AMG 334 significantly reduces monthly migraine days in chronic migraine
Sep 19, 2016News Hour: Novartis announced detailed Phase II results showing the fully human monoclonal antibody AMG 334 (erenumab) demonstrated a statistically significant reduction in monthly migraine days compared with placebo in patients with chronic migraine (CM). Significantly... -
Novartis bid to sell new biosimilar crimped by U.S. court battles
Aug 31, 2016News Hour: Novartis has won U.S. approval for a copy of Amgen’s blockbuster arthritis drug Enbrel, but the Swiss drugmaker’s bid to muscle in on the medicine’s $4.7 billion (3.57 billion pounds) in annual U.S. revenue... -
Six leading scientists to receive prestigious novartis prizes for immunology at 16th international congress of immunology
Aug 22, 2016News Hour: Novartis announced that six scientists will receive the 2016 Novartis Prizes for Immunology at the upcoming 16th International Congress of Immunology (ICI) in Melbourne, Australia on Aug 22, 2016. The Novartis Prizes for Immunology... -
Alcon achieves US approval for CyPass® Micro-Stent
Aug 2, 2016News Hour: Alcon, the global leader in eye care and a division of Novartis, announced today that it has achieved FDA approval for the CyPass® Micro-Stent, a micro-invasive glaucoma surgical (MIGS) device to treat patients with... -
Alcon launches Dailies Total1® Multifocal contact lenses, the first and only water gradient lenses designed for people with presbyopia
Jul 19, 2016News Hour: Alcon, the global leader in eye care and a division of Novartis, introduces Dailies Total1 Multifocal contact lenses for people with presbyopia. This innovative multifocal lens provides both seamless distant, intermediate and near... -
New scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016
Jun 24, 2016News Hour: Novartis announced that it will present 33 scientific abstracts at the Annual European Congress of Rheumatology (EULAR 2016) in London, UK. This includes new long-term analyses suggesting Cosentyx® (secukinumab) may lead to higher responses...
